Lung Cancer

Taofeek Owonikoko, MD, PhD, highlights investigational agents and ongoing clinical trials in SCLC he looks forward to.

Experts provide insights on choosing the optimal therapy in patients with small cell lung cancer in the second line and beyond.

Treatment with durvalumab and concurrent radiotherapy provided a significant benefit in progression-free survival in patients with locally advanced non–small cell lung cancer, meeting the primary end point of the phase 2 DOLPHIN trial.

Although frontline treatment with avelumab resulted in a longer overall survival and progression-free survival than that observed with platinum-based chemotherapy in patients with advanced non–small cell lung cancer and high PD-L1 positivity, this difference did not achieve statistical significance.

Sunvozertinib monotherapy produced meaningful responses in patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations who received prior treatment with platinum-based chemotherapy, according to pooled data from the phase 1 WU-KONG1 and WU-KONG2 trials, plus the phase 2 WU-KONG6 trial.

Brandon S. Sheffield, MD, discusses the economic cost of delaying treatment while conducting biomarker testing in non–small cell lung cancer.

Benjamin Levy, MD, discusses the efficacy findings of the combination of datopotamab deruxtecan and pembrolizumab, with or without chemotherapy, in non–small cell lung cancer.

There is an obvious way to double survival in patients with lung cancer in the next 5 years: remove barriers to screening, especially for high-risk populations.

The FDA has granted an orphan drug designation to THIO for the treatment of patients with small cell lung cancer.

Focusing on ALK-rearranged non–small cell lung cancer, expert panelists review data behind alectinib, brigatinib, and lorlatinib.

Expert perspectives on the management of KRAS G12C–mutant non–small cell lung cancer in the context of novel targeted agents.

The combination of datopotamab deruxtecan and pembrolizumab, with or without platinum-based chemotherapy, displayed promising efficacy and a manageable safety profile in patients with advanced/metastatic non–small cell lung cancer.

The combination of pembrolizumab and etoposide maintained benefits in overall survival (OS) and progression-free survival vs etoposide plus placebo in patients with previously untreated extensive-stage small cell lung cancer.

First-line treatment with tremelimumab, durvalumab, and chemotherapy elicited overall survival and progression-free survival benefits in patients with metastatic nonsquamous cell non–small cell lung cancer harboring STK11, KEAP1, and KRAS mutations.

Alexander I. Spira, MD, PhD, FACP, discusses additional studies investigating the use of lazertinib and amivantamab in EGFR-mutated non–small cell lung cancer.

The combination of talazoparib and temozolomide elicited an objective response rate of 39.3% in patients with extensive-stage small cell lung cancer who were relapsed or refractory to a frontline platinum-based chemotherapy regimen, according to data from a phase 2 UCLA/TRIO-US L-07 trial.

Melina Elpi Marmarelis, MD, discusses the efficacy of lazertinib and amivantamab-vmjw plus chemotherapy in patients with EGFR-mutated non–small cell lung cancer.

Temozolomide in combination with nivolumab induced a promising overall response rates in patients who previously received chemotherapy for extensive-stage small cell lung cancer.

New combinations and strategies are needed for patients with non–small cell lung cancer who progress after first-line chemoimmunotherapy after results of a retrospective analysis showed modest efficacy with second-line chemotherapy.

EGFR C797X mutations have become a leading mechanism of acquired resistance following treatment with the third-generation EGFR inhibitor osimertinib, outpacing MET amplification.

Amivantamab in combination with lazertinib plus carboplatin and pemetrexed elicited encouraging responses in pretreated patients with EGFR-mutant non–small cell lung cancer, according to findings from the phase 1 CHRYSALIS-2 trial.

Drs Edward S. Kim and Alexander Spira answer viewer questions on ADCs in non-small cell lung cancer.

An overall survival trend in favor of adjuvant atezolizumab over best supportive care was observed in patients with stage II to IIIA resected non–small cell lung cancer with a PD-L1 tumor cell (TC) expression of at least 1%, with a clinically meaningful OS trend noted in those with a PD-L1 TC expression of 50% or higher.

The addition of nivolumab to chemotherapy provided progression-free survival and overall survival benefits compared with chemotherapy alone in patients with stage IIIA/B non–small cell lung cancer.

The combination of pembrolizumab and lenvatinib generated promising clinical activity with a manageable safety profile in pretreated patients with malignant pleural mesothelioma.

The combination of sotorasib and the small molecule SHP2 inhibitor RMC-4630 led to an investigator-assessed objective response rate of 27% and 50% in pretreated and KRAS G12C inhibitor–naïve patients with non–small cell lung cancer, respectively.

The robust efficacy achieved with tepotinib in patients with non–small cell lung cancer harboring MET exon 14 skipping alterations was independently confirmed in data from the primary analysis of cohort C of the phase 2 VISION trial.

A lead-in dosing strategy for the combination of sotorasib in combination with either pembrolizumab or atezolizumab showed promising efficacy and relatively low rates of hepatotoxicity in patients with KRAS G12C–positive non–small cell lung cancer.

Sitravatinib in combination with tislelizumab demonstrated a confirmed investigator-assessed overall response rate of 30.4% in patients with PD-L1–positive, treatment-naïve, locally advanced or metastatic squamous non–small cell lung cancer.

GDC-6036, a novel KRAS G12C inhibitor, produced encouraging antitumor activity with a manageable safety profile as a single agent in previously treated patients with KRAS G12C–mutated NSCLC, according to data from a phase 1a trial.